View Cart  

Endo Petitions FDA to Keep Opana Control as More ANDAs Are Submitted

A A
Endo Pharmaceuticals is petitioning the FDA to require generics referencing its crush-resistant pain drug, Opana ER CRF, demonstrate they are similarly crush-resistant.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00